Innovent Biopharmaceutical Transformation
Innovent is Your Preferred Partner in China
"from product development to commercial launch"
Pioneering MNC
Partnerships
Building Platforms
for the Future
Unlocking Value of
Regional
Best-in-class
Biotech Assets
Partnering
Lilly
"Lilly/Innovent" most comprehensive
partnership after 7 years
•
.
Tyvyt: Co-development, co-
commercialization in China in 2015
Multiple Expansions:
✓ PD1 Bispecifics (2015)
✓ GLP-1/GCGR (2019)
✓ Tyvyt - Ex-China (2020)
✓ Cyramza and Retsevmo (2022)
Innovent
•
•
•
Roche
Synaffix
connect to cure
BIOTHERAPEUTICS
Adimab
EpimAb
Hanmi
BOLT
ALECTOR
劲方医药
GENFLEET
Coherus
Incyte
UNION
Biotherapeutics
Partnering to Build Capabilities
THERAPEUTICS.
Untapping Portfolio Potentials
Multi-Asset Roche partnership
BOLT Multi-Asset ISAC
partnership
Synaffix-ADC partnership
Incyte - Late Stage
✓ 3 Late stage assets - co-
developed globally, now
launching in China and Taiwan
Alector Early Stage
Genfleet
Early Stage
Confidential
Copyright©2022 Innovent
In-house R&D
•
BIOSCIENCES
etana
Biotech
亞盛醫藥
Ascentage Pharma
AnHeart
Therapeutics
BLAK
Assisting Local companies to
outcompete MNCs in China
Avastin biosimilar out-license:
✓ Coherus - North America
✓ Etana - Indonesia
•
Local partnering:
✓ AnHeart's ROS1
LOKNA
Lane Ther
✓ Ascentage's BCR-Abl and BCL2
✓ IASO Bio's BCMA CART
Establishing a world-class
biologic platform
✓ Immunology science
✓ Cancer biology
✓ Protein engineering
32
32View entire presentation